Evidence map›Paper›PMID 30929579›Full record

ArticleCirculation research2019

CRRL269.

Yang Chen, Gail J Harty, Ye Zheng, Seethalakshmi R Iyer, Shinobu Sugihara, S Jeson Sangaralingham, Tomoko Ichiki, Joseph P Grande, Hon-Chi Lee, Xiaoli Wang and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies.Hypertension research : official journal of the Japanese Society of Hypertension · 2021
    Review
  10. Review
  11. Review
  12. Review
  13. Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP.American journal of physiology. Regulatory, integrative and comparative physiology · 2020
    Article
  14. Dexmedetomidine Enhances AutophagyFrontiers in pharmacology · 2020
    Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yang ChenFrom the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.
Gail J HartyFrom the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.
Ye ZhengFrom the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.
Seethalakshmi R IyerFrom the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.
Shinobu SugiharaFrom the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.
S Jeson SangaralinghamFrom the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.
Tomoko IchikiFrom the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.
Joseph P GrandeDepartment of Laboratory Medicine and Pathology (J.P.G.), Mayo Clinic, Rochester, MN.
Hon-Chi LeeDepartment of Cardiovascular Medicine (H.-C.L., X.L.W.), Mayo Clinic, Rochester, MN.
Xiaoli WangDepartment of Cardiovascular Medicine (H.-C.L., X.L.W.), Mayo Clinic, Rochester, MN.
John C BurnettFrom the Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (Y.C., G.J.H., Y.Z., S.R.I., S.S., S.J.S., T.I., J.C.B.), Mayo Clinic, Rochester, MN.
Mayo Clinic · USMayo Clinic in Florida · USMayo Clinic in Arizona · US

Funding

INTRARENAL REGULATION OF SODIUM EXCRETIONR01HL036634 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 1987 to 2019
$6.5M
Type 2 Diabetes and Vascular BK Channel RegulationR01HL074180 · NHLBI · MAYO CLINIC ROCHESTER · PI LEE, HON-CHI · 2003 to 2018
$4.8M
Cardiorenal Fibrosis: Biology and TherapeuticsR01HL132854 · NHLBI · MAYO CLINIC ROCHESTER · PI SANGARALINGHAM, SASANTHA JESON · 2016 to 2020
$2.0M
NHLBI NIH HHS R01 HL036634NHLBI NIH HHS R01 HL074180NHLBI NIH HHS R01 HL132854
6 · The paper itself

Abstract

rationaleAcute kidney injury (AKI) has a high prevalence and mortality in critically ill patients. It is also a powerful risk factor for heart failure incidence driven by hemodynamic changes and neurohormonal activation. However, no drugs have been approved by the Food and Drug Administration. Endogenous pGC-A (particulate guanylyl cyclase A receptor) activators were reported to preserve renal function and improve mortality in AKI patients, although hypotension accompanied by pGC-A activators have limited their therapeutic potential.

objectiveWe investigated the therapeutic potential of a nonhypotensive pGC-A activator/designer natriuretic peptide, CRRL269, in a short-term, large animal model of ischemia-induced AKI and also investigated the potential of uCNP (urinary C-type natriuretic peptide) as a biomarker for AKI. METHODS AND

resultsWe first showed that CRRL269 stimulated cGMP generation, suppressed plasma angiotensin II, and reduced cardiac filling pressures without lowering blood pressure in the AKI canine model. We also demonstrated that CRRL269 preserved glomerular filtration rate, increased renal blood flow, and promoted diuresis and natriuresis. Further, CRRL269 reduced kidney injury and apoptosis as evidenced by ex vivo histology and tissue apoptosis analysis. We also showed, compared with native pGC-A activators, that CRRL269 is a more potent inhibitor of apoptosis in renal cells and induced less decreases in intracellular Ca

conclusionsOur study supports developing CRRL269 as a novel renocardiac protective agent for AKI treatment.

Indexed as

Acute Kidney InjuryAngiotensin IIAnimalsApoptosisBiomarkersBlood PressureCyclic GMPDiuresisDogsGlomerular Filtration RateMaleNatriuresisNatriuretic Peptide, C-TypeNatriuretic PeptidesReceptors, Atrial Natriuretic FactorRenal AgentsAngiotensin IIatrial natriuretic factor receptor ABiomarkersCRRL269Cyclic GMPNatriuretic Peptide, C-TypeNatriuretic PeptidesReceptors, Atrial Natriuretic FactorRenal Agentsacute kidney injuryapoptosiscardiorenal syndromeheart failurenatriuretic peptide

Identifiers

PMID30929579
PMCPMC6512967
OpenAlexW2931240255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.